B A C K G R O U N D
This protocol is based on the protocol from the published review on ab interno trabecular bypass surgery with Trabectome for open angle glaucoma (Hu 2016).
Description of the condition
Glaucoma is a progressive optic neuropathy, affecting 3.5% of people aged 40 to 80 years (Tham 2014) . It is the leading cause of irreversible blindness, affecting over 64 million people globally (Tham 2014 ). This figure is expected to increase to 110 million people by 2040. Open angle glaucoma (OAG) is the commonest type, accounting for 86% of cases (Tham 2014). In one large population cohort, one in six people with OAG became bilaterally blind (Peters 2013). Angle closure glaucoma is less common than OAG, but is more likely to result in bilateral blindness. The only proven way to prevent vision loss is to reduce the In the past years, a number of minimally-invasive surgical techniques have been developed with the aim of achieving long-term reduction of IOP with a better safety profile than conventional surgery (Francis 2011a). Among them, endoscopic cyclophotocoagulation (ECP) is a cyclodestructive procedure developed by Martin Uram in 1992 (Uram 1995).
How the intervention might work
The ciliary body is the site of aqueous humour production. In cyclodestructive procedures, the secretory epithelium of the ciliary epithelium is damaged, which leads to reduced aqueous humour secretion and lower IOP. Endoscopic cyclophotocoagulation incorporates a diode laser, an aiming beam and video camera imaging. Direct visualisation of the ciliary endothelium allows the delivering of energy precisely to the ciliary processes in a highly titratable fashion, while minimalizing collateral damage to the surrounding tissue.
Why it is important to do this review
Consultation with patients and healthcare professionals has identified a need for better treatments for glaucoma (James Lind Alliance 2013). Minimally-invasive glaucoma surgeries (MIGS) carry the possibility of safe and effective long-term reduction of IOP, removing concerns about permanent vision loss due to nonadherence to eye-drops. A single treatment may also be more acceptable to patients than daily and indefinite self-administration of eyedrops. Initial results of ECP were reported in 1992 by Uram (Uram 1992), where he treated 10 eyes with neovascular glaucoma. Since then, several studies have demonstrated the IOP-lowering effect of ECP in different glaucoma forms (Chen 1997; Francis 2011b; Lima 2004). In the light of the potential benefits for patients and the widespread uptake of the technique, it is important to critically evaluate the evidence for the efficacy and safety of ECP treatment. Importantly, ECP may be combined with phacoemulsification (cataract surgery), a sight-restoring operation to remove the natural lens of the eye when it has lost clarity. Since phacoemulsification itself reduces IOP (Mansberger 2012), we will specifically examine the evidence for the efficacy of ECP when combined with phacoemulsification in comparison to phacoemulsification alone. This Cochrane review will be conducted in parallel with other reviews currently undertaken by the Cochrane Eyes and Vision MIGS Consortium, which includes minimally-invasive glaucoma surgery (MIGS) techniques and devices such as the Trabectome (NeoMedix, Tustin, California) (Hu 2016), Hydrus Schlemm's canal Microstent (Ivantis Inc., Irvine, California) (Otarola 2017), XEN Glaucoma Implant (AqueSys Implant, Aliso Viejo, California) and IStent or IStent inject (Glaukos Corporation, Laguna Hills, California).
O B J E C T I V E S
The main objective is to assess the results at two years of ECP for OAG and primary angle closure in comparison to conventional medical, laser, or surgical treatment, in terms of efficacy and safety. A secondary objective will be to examine the effect of the effects of ECP treatment with concomitant phacoemulsification in comparison to ECP treatment alone.
M E T H O D S Criteria for considering studies for this review

Types of studies
We will include randomised controlled trials (RCTs) only. We will include reports of RCTs prepared in any language, irrespective of their publication status.
Types of participants
Participants will have OAG of any type, including primary and secondary OAG, or primary angle closure with raised IOP with or without glaucoma (PAC-OHT or PACG). Secondary forms of angle closure will be excluded. As there are no universally-accepted criteria by which glaucoma may be defined, we will permit studies to use their own definitions of glaucoma. In addition, participants with ocular hypertension, normal tension glaucoma, or possible glaucoma (suspects for glaucoma) will be included. We will not apply any restrictions regarding location, setting, or demographic factors.
Types of interventions
The intervention will be ECP. Although it is possible to deliver variable degrees of treatment on the ciliary body with titratable power levels, we will not apply any particular inclusion or exclusion criteria around these or other treatment delivery parameters. There are two main approaches to reach ciliary body: via limbal or pars plana entry. As the latter requires anterior vitrectomy, it cannot be considered as MIGS, and will not be part of this review. We will compare ECP to:
1. laser treatment (selective laser trabeculoplasty or argon laser trabeculoplasty); 2. other MIGS techniques; 3. conventional glaucoma surgery (trabeculectomy) 4. medical therapy; or 5. in combination with phacoemulsification compared with phacoemulsification alone (since phacoemulsification cataract surgery is known to reduce IOP (Mansberger 2012)).
Types of outcome measures
We will not use the reporting of particular outcomes as a criterion for eligibility for review. We will not exclude studies from review solely on the grounds of an outcome of interest not being reported.
Primary outcomes
The primary outcome will be the proportion of participants who are drop-free (not using eye drops) at two years after randomisations. Several different glaucoma outcome measures have been specified as primary outcomes in other Cochrane Reviews and protocols (Ismail 2015) . A recent study classified IOP, visual field, safety, and anatomic outcomes as being highly important to glaucoma experts (Ismail 2016). A panel of patients from the Patient and Public Involvement Group of the National Institute for Health Research (NIHR) Biomedical Research Centre for Ophthalmology identified drop-free disease control as a highly-valued outcome (unpublished). We chose a participant-centred primary outcome. In assessing this outcome, we will report how prescribing of IOPlowering eye drops was determined during follow-up. We will examine whether the people measuring IOP and those deciding upon the prescribing of IOP-lowering eye drops were masked to treatment group.
Secondary outcomes
Secondary outcomes will be:
1. Mean change in IOP, measured using Goldmann applanation tonometry, from randomisations to two years.
2. The proportions of participants experiencing intra-and postoperative complications from randomisations to two-year follow-up including but not restricted to the following:
• Loss of visual acuity (more than two Snellen lines or more than 0.3 logMAR, according to the method of recording visual acuity; or loss of light perception).
• Bleeding, as recorded by the investigators.
• Endophthalmitis, as recorded by the investigators.
• IOP spikes (postoperative rise in IOP, measured using Goldmann applanation tonometry, of more than 10 mmHg compared to the previous assessment, including during the first postoperative month).
• Hypotony (significant postoperative reduction of IOP to 6 mmHg or below).
• Phthisis bulbi, as recorded by the investigators.
• Secondary surgery, as recorded by the investigators. 3. Change from randomisations to two-year follow-up in health-related quality of life measure.
Search methods for identification of studies Electronic searches
The Cochrane Eyes and Vision Information Specialist will search the following electronic databases for randomised controlled trials and controlled clinical trials. There will be no language or publication year restrictions.
•
• US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5);
• World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp) (Appendix 6).
Searching other resources
We will search the reference lists of included studies for other possible studies and will contact any individuals or organisations whom we believe may have conducted or be conducting relevant RCTs. We will also search the website of the manufacturer (Endo Optiks, Little Silver, NJ, USA: endooptiks.com) for any information on forthcoming trials.
Data collection and analysis
Selection of studies
Two review authors working independently will screen titles and abstracts of all articles identified by the search using web-based review management software (Covidence 2015). If abstracts are not available, we will screen full-text articles. Two review authors will independently assess full-text reports of all potentially eligible studies. If there is disagreement regarding eligibility, a third review author will arbitrate. If any full-text reports are rejected, we will record the reasons for this.
Data extraction and management
We will extract data from reports of included studies using a data collection form, which will be developed and piloted on the first five studies included. Two review authors will work independently to extract study characteristics from reports of each study and enter the data into Review Manager 5 (RevMan 5) (Review Manager 5 2014). If there is disagreement, a third review author will arbitrate. We will collect the following information on the characteristics of included studies (Appendix 7):
• Year of publication.
• Year of study.
• Country of study.
• Sample size.
• Participation rate.
• Method of recruitment.
• Eligibility criteria.
• Diagnostic criteria.
• Method of randomisations.
• Method of masking.
• Number of study arms.
• Types of participants.
• Types of interventions.
• Types of comparators.
• Use of phacoemulsification at the same time as the intervention.
We will collect the following data regarding outcomes (Appendix 7):
• IOP at baseline.
• IOP at follow-up.
• Number of glaucoma medications at baseline.
• Number of glaucoma medications at follow-up.
• Intraoperative complications.
• Postoperative complications or secondary surgery.
• Duration of follow-up.
• Loss to follow-up.
• Intervals at which outcomes were assessed.
Where data on included studies are missing or unclear, we will contact the individuals or organisations involved to obtain clarification. We will collect and use the most detailed numerical data available to facilitate analyses of included studies. We will attempt to obtain these data from individuals or organisations in preference to less precise methods such as extracting numeric data from graphs. If this is necessary, two review authors will independently extract the data and a third review author will arbitrate in case of disagreement.
Assessment of risk of bias in included studies
We will use the latest version of the Cochrane 'Risk of bias' tool as described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) to assess the risk of bias and assign judgements of this for included studies.
Measures of treatment effect
The primary outcome is the proportion of participants who are drop-free two years after randomisations. We will use the risk ratio as the measure of effect for this outcome. We will report mean change in IOP from randomisations to two years after randomisations. Secondary safety outcomes will be reported as risk ratios. Health-related quality of life outcomes will be reported as differences in means or risk ratios for continuous and binary data, respectively.
Unit of analysis issues
We will assess whether included studies have included one or two eyes from each participant and whether or not randomisations has been conducted at the level of the participant or the eye. There is a potential for medical treatments, such as topical beta blockers, used for one eye to influence the outcome in the other eye (Piltz 2000). Surgery to lower IOP in one eye may also affect the IOP of the fellow eye (Radcliffe 2010). Therefore, we will exclude studies that have adopted a paired design.
Dealing with missing data
We will endeavour to minimize missing outcome data by contacting individuals and organisations to obtain them. If the data are unavailable, but the level of missing data in each group and reasons for missing data in each group are similar, we may simply analyse available case data if an intention-to-treat (ITT) analysis has not been performed. If authors have conducted their own ITT analysis despite missing data, we will document whether they provide any justification for the method they have used to deal with missing data and whether they have compared their ITT result with an available case result.
Assessment of heterogeneity
We will assess the heterogeneity between trials by careful examination of the study reports, assessing forest plots, and an examination of the I 2 value. We will consider I 2 values greater than 50% as indicative of substantial heterogeneity and, therefore, suggestive that meta analysis might not be wise; however, we will give consideration to the consistency of the effect estimates. If all estimates are in the same direction, we might meta-analyse even where heterogeneity is evident; we will comment on the heterogeneity.
Assessment of reporting biases
We will use a funnel plot to assess the risk of publication bias if there are more than 10 trials within our review.
Data synthesis
We will undertake a meta-analysis where data appear clinically, methodologically, and statistically homogeneous. We will check that participants, interventions, comparators, and outcomes are sufficiently similar to give a clinically meaningful result and that our I 2 result indicates little inconsistency (i.e. I 2 less than 50%). If all estimates are in the same direction, we might meta-analyse even where heterogeneity is evident, but will comment on this. We will use a random-effects model unless there are fewer than three eligible studies, in which case we will use a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We will undertake a subgroup analysis. The effect modifier to be examined will be use of phacoemulsification as a co-intervention. Phacoemulsification has been shown to reduce IOP (Mansberger 2012). We will therefore analyse whether the effect of ECP surgery differs depending on whether phacoemulsification is used as a cointervention.
Sensitivity analysis
We will assess the impact of including studies at high risk of bias for an outcome in one or more key domains.
Summary of findings
We will prepare tables to summarise the findings of the review, including the assessment of the quality of evidence for all outcomes using the GRADE approach (GRADEpro 2014). All outcomes considered in the review will be reported in the summary. We will report the following outcomes in the 'Summary of findings' table and the comparison groups described under Types of interventions: ECP compared with laser treatment, other MIGS techniques, conventional glaucoma surgery (trabeculectomy), medical therapy or in combination with phacoemulsification compared with phacoemulsification alone.
1. Proportion of participants who are drop-free (not using eye drops) at two years follow-up.
2. Mean change in number of IOP-lowering drops taken per day from baseline to two years follow-up.
3. Mean change in IOP, measured using Goldmann applanation tonometry, from baseline to two years follow-up.
4. Health-related quality of life at two years follow-up. 5. Intraoperative complications. 6. Postoperative complications up to two years follow-up. 7. Secondary glaucoma surgery, including laser, as recorded by the investigators of the included trials between baseline and two years follow-up.
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